Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Practical Procedures & Aesthetic Dentistry : PPAD|June 24, 2008
Classification of clinical attributes in tooth appearanceSteven P Weinstein
Development, Growth & Differentiation|June 7, 2023
Increased Potassium Conductance in Rana Follicles after Stimulation by Pituitary Extract: (amphibian follicle/meiotic maturation/gonadotropin/KSteven P Weinstein, Gene A Morrill, Adele B Kostellow
The Journal of Rheumatology|July 17, 2014
Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety studyJohn S Sundy, H Ralph Schumacher, Alan Kivitz, et al.
Clinical Therapeutics|October 4, 2012
Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension studyHal M Hoffman, Martin L Throne, Niran J Amar, et al.
Arthritis Care & Research|May 3, 2012
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy studyH Ralph Schumacher, Robert R Evans, Kenneth G Saag, et al.
Arthritis Research & Therapy|February 5, 2013
Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparatorRobert A Terkeltaub, H Ralph Schumacher, John D Carter, et al.
Rheumatology (Oxford, England)|March 15, 2013
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trialEssack Mitha, H Ralph Schumacher, Leon Fouche, et al.
Arthritis and Rheumatism|August 1, 2008
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studiesHal M Hoffman, Martin L Throne, N J Amar, et al.
Arthritis and Rheumatism|January 7, 2012
Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trialH Ralph Schumacher, John S Sundy, Robert Terkeltaub, et al.
Arthritis and Rheumatism|August 1, 2008
A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndromeRaphaela Goldbach-Mansky, Sharukh D Shroff, Mildred Wilson, et al.
Pageof 2